CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway

CD33 (siglec-3), a well-known target in leukemia therapy, is an inhibitory sialoadhesin expressed in human leukocytes of the myeloid lineage and some lymphoid subsets, including NK cells. It may constitute a control mechanism of the innate immune system; nevertheless, its role as an inhibitory recep...

Full description

Saved in:
Bibliographic Details
Main Authors: Trinidad Hernández-Caselles, Rubén Corral-San Miguel, Antonio José Ruiz-Alcaraz, Pilar García-Peñarrubia
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2019/6032141
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849683380326629376
author Trinidad Hernández-Caselles
Rubén Corral-San Miguel
Antonio José Ruiz-Alcaraz
Pilar García-Peñarrubia
author_facet Trinidad Hernández-Caselles
Rubén Corral-San Miguel
Antonio José Ruiz-Alcaraz
Pilar García-Peñarrubia
author_sort Trinidad Hernández-Caselles
collection DOAJ
description CD33 (siglec-3), a well-known target in leukemia therapy, is an inhibitory sialoadhesin expressed in human leukocytes of the myeloid lineage and some lymphoid subsets, including NK cells. It may constitute a control mechanism of the innate immune system; nevertheless, its role as an inhibitory receptor remains elusive. Using human NK cells as a cellular model, we analyzed CD33 inhibitory function upon different activating receptors. In high-cytotoxicity NKL cells, CD33 displayed a prominent inhibition on cytotoxicity triggered by the activating receptors NKG2D and, in a lower extent, 2B4, whereas it did not inhibit NKp46-induced cytotoxicity. NKp46 was partially inhibited by CD33 only when low-cytotoxicity NKL cells were tested. CD33 triggering did not inhibit IFN-γ secretion, contrasting with ILT-2 and CD94/NKG2A inhibitory receptors that inhibited cytotoxicity and IFN-γ secretion induced by all activating receptors tested. CD33-mediated inhibition of NKG2D-induced triggering involved Vav1 dephosphorylation. Our results support the role of CD33 as an inhibitory receptor preferentially regulating the NKG2D/DAP10 cytotoxic signaling pathway, which could be involved in self-tolerance and tumor and infected cell recognition.
format Article
id doaj-art-dca3b2434f034521abbc3cbfeaff4bca
institution DOAJ
issn 2314-8861
2314-7156
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-dca3b2434f034521abbc3cbfeaff4bca2025-08-20T03:23:55ZengWileyJournal of Immunology Research2314-88612314-71562019-01-01201910.1155/2019/60321416032141CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating PathwayTrinidad Hernández-Caselles0Rubén Corral-San Miguel1Antonio José Ruiz-Alcaraz2Pilar García-Peñarrubia3Departamento de Bioquímica, Biología Molecular B e Inmunología, Faculty of Medicine, IMIB-University of Murcia, Murcia, SpainDepartamento de Bioquímica, Biología Molecular B e Inmunología, Faculty of Medicine, IMIB-University of Murcia, Murcia, SpainDepartamento de Bioquímica, Biología Molecular B e Inmunología, Faculty of Medicine, IMIB-University of Murcia, Murcia, SpainDepartamento de Bioquímica, Biología Molecular B e Inmunología, Faculty of Medicine, IMIB-University of Murcia, Murcia, SpainCD33 (siglec-3), a well-known target in leukemia therapy, is an inhibitory sialoadhesin expressed in human leukocytes of the myeloid lineage and some lymphoid subsets, including NK cells. It may constitute a control mechanism of the innate immune system; nevertheless, its role as an inhibitory receptor remains elusive. Using human NK cells as a cellular model, we analyzed CD33 inhibitory function upon different activating receptors. In high-cytotoxicity NKL cells, CD33 displayed a prominent inhibition on cytotoxicity triggered by the activating receptors NKG2D and, in a lower extent, 2B4, whereas it did not inhibit NKp46-induced cytotoxicity. NKp46 was partially inhibited by CD33 only when low-cytotoxicity NKL cells were tested. CD33 triggering did not inhibit IFN-γ secretion, contrasting with ILT-2 and CD94/NKG2A inhibitory receptors that inhibited cytotoxicity and IFN-γ secretion induced by all activating receptors tested. CD33-mediated inhibition of NKG2D-induced triggering involved Vav1 dephosphorylation. Our results support the role of CD33 as an inhibitory receptor preferentially regulating the NKG2D/DAP10 cytotoxic signaling pathway, which could be involved in self-tolerance and tumor and infected cell recognition.http://dx.doi.org/10.1155/2019/6032141
spellingShingle Trinidad Hernández-Caselles
Rubén Corral-San Miguel
Antonio José Ruiz-Alcaraz
Pilar García-Peñarrubia
CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
Journal of Immunology Research
title CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
title_full CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
title_fullStr CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
title_full_unstemmed CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
title_short CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
title_sort cd33 siglec 3 inhibitory function role in the nkg2d dap10 activating pathway
url http://dx.doi.org/10.1155/2019/6032141
work_keys_str_mv AT trinidadhernandezcaselles cd33siglec3inhibitoryfunctionroleinthenkg2ddap10activatingpathway
AT rubencorralsanmiguel cd33siglec3inhibitoryfunctionroleinthenkg2ddap10activatingpathway
AT antoniojoseruizalcaraz cd33siglec3inhibitoryfunctionroleinthenkg2ddap10activatingpathway
AT pilargarciapenarrubia cd33siglec3inhibitoryfunctionroleinthenkg2ddap10activatingpathway